Comparison of single and combination diuretics on glucose tolerance (PATHWAY-3): protocol for a randomised double-blind trial in patients with essential hypertension by Brown, MJ et al.
Comparison of single and combination
diuretics on glucose tolerance
(PATHWAY-3): protocol for a
randomised double-blind trial in
patients with essential hypertension
Morris J Brown,1,2,3 Bryan Williams,2,3,4 Thomas M MacDonald,2,3,5
Mark Caulfield,3,6 J Kennedy Cruickshank,7 Gordon McInnes,8 Peter Sever,3,9
David J Webb,3,10 Jackie Salsbury,1 Steve Morant,5 Ian Ford2,3,11
To cite: Brown MJ,
Williams B, MacDonald TM,
et al. Comparison of single
and combination diuretics on
glucose tolerance (PATHWAY-
3): protocol for a randomised
double-blind trial in patients
with essential hypertension.
BMJ Open 2015;5:e008086.
doi:10.1136/bmjopen-2015-
008086
▸ Prepublication history for
this paper is available online.
To view these files please
visit the journal online
(http://dx.doi.org/10.1136/
bmjopen-2015-008086).
Received 2 March 2015
Revised 30 April 2015
Accepted 15 June 2015
▸ http://dx.doi.org/10.1136/
bmjopen-2015-007645
▸ http://dx.doi.org/10.1136/
bmjopen-2015-008951
For numbered affiliations see
end of article.
Correspondence to
Professor Morris J Brown;
morris.brown@cai.cam.ac.uk
ABSTRACT
Introduction: Thiazide diuretics are associated with
increased risk of diabetes mellitus. This risk may arise
from K+-depletion. We hypothesised that a K+-sparing
diuretic will improve glucose tolerance, and that
combination of low-dose thiazide with K+-sparing
diuretic will improve both blood pressure reduction
and glucose tolerance, compared to a high-dose
thiazide.
Methods and analysis: This is a parallel-group,
randomised, double-blind, multicentre trial, comparing
hydrochlorothiazide 25–50 mg, amiloride 10–20 mg
and combination of both diuretics at half these doses.
A single-blind placebo run-in of 1 month is followed by
24 weeks of blinded active treatment. There is forced
dose-doubling after 3 months. The Primary end point
is the blood glucose 2 h after oral ingestion of a 75 g
glucose drink (OGTT), following overnight fasting. The
primary outcome is the difference between 2 h glucose
at weeks 0, 12 and 24. Secondary outcomes include
the changes in home systolic blood pressure (BP) and
glycated haemoglobin and prediction of response by
baseline plasma renin. Eligibility criteria are: age 18–
79, systolic BP on permitted background treatment
≥140 mm Hg and home BP ≥130 mm Hg and one
component of the metabolic syndrome additional to
hypertension. Principal exclusions are diabetes,
estimated-glomerular filtration rate <45 mL/min,
abnormal plasma K+, clinic SBP >200 mm Hg or DBP
>120 mm Hg (box 2). The sample size calculation
indicates that 486 patients will give 80% power at
α=0.01 to detect a difference in means of 1 mmol/L
(SD=2.2) between 2 h glucose on hydrochlorothiazide
and comparators.
Ethics and dissemination: PATHWAY-3 was
approved by Cambridge South Ethics Committee,
number 09/H035/19. The trial results will be published
in a peer-reviewed scientific journal.
Trial registration numbers: Eudract number 2009-
010068-41 and clinical trials registration number:
NCT02351973.
INTRODUCTION
Thiazide and thiazide-like diuretics are
widely used. However, such diuretics are asso-
ciated with increased risk of developing dia-
betes mellitus.1 This risk may arise from
K+-depletion and be avoided by use of
K+-sparing diuretics. We therefore hypothe-
sised that a K+-sparing diuretic has a beneﬁ-
cial inﬂuence on glucose tolerance
compared to a thiazide, and that the use of
low-dose thiazide combined with a K+-sparing
diuretic may achieve similar blood pressure
reduction, but improved glucose tolerance,
compared to a high-dose thiazide.
Diuretics are no longer used at doses
achieving maximum reduction in BP. This is
because of the evidence that higher doses
are associated with increased risk of diabetes
mellitus (DM), and an extrapolation from
small studies in the 1980’s and 90’s that
maximal blood pressure reductions were
achieved by low-dose thiazides.2–5 However,
unpublished dose-titration data from
INSIGHT (ﬁgure 1A), where the average age
was 60, shows as steep a dose–response for
hydrochlorothiazide as for nifedipine in
patients (right panel) whose dose was
doubled after 2 weeks.6 Amiloride has never
Strengths and limitations of this study
▪ This is a parallel-group, randomised, double-blind,
multicentre trial.
▪ Six months may not be sufficient to permit
detection of new onset diabetes.
▪ Two of the randomised treatments are available
in the UK only in combination formulations con-
taining different doses from those under study.
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been fully investigated at doses equi-effective with thia-
zides, and is used mainly in an ancillary K+-sparing role.7
A diuretic crossover study (‘SALT’) conﬁrmed that in
low-renin patients bendroﬂumethiazide 2.5 mg is not
maximal, and showed either spironolactone or amiloride
to be effective alternatives to the higher dose (ﬁgure
1B).8 Several indices in SALT indicated that even 5 mg
of bendroﬂumethiazide was a less effective natriuretic
than the K+-sparing diuretics, perhaps because it lowers
blood pressure (BP) partly through vasodilation.9 The
difference in mechanisms raised the possibility, to be
explored by PATHWAY-3, that the diuretics will be found
to have an additive effect on BP.
Diuretics and new-onset diabetes: A major attraction of
K+-sparing diuretics is the possibility that they will offset
the diabetogenic potential of thiazides. Since they have
not been compared in hypertension outcome trials, and
diabetes (DM) has not been an end point in heart failure
studies of spironolactone or eplerenone, we do not know
for certain whether they are clean in this respect.
Short-term studies suggest they are.10 Interestingly in
INSIGHT there was no excess of DM in patients receiving
hydrochlorothiazide (HCTZ) 25 mg, which was combined
with amiloride 2.5 mg, but increased by 30% in patients
on HCTZ/amiloride 50/5 mg.6 In PATHWAY-3, we use the
oral glucose tolerance test (OGTT) to provide an end
point for each subject. This strategy was previously used to
demonstrate a difference after just 12 weeks of dosing with
a thiazide diuretic.11 In the STAR study, which compared
200 markedly obese patients randomly assigned to either
ACE inhibitor +Ca++ blocker, or ARB+thiazide, the subjects
had impaired glucose tolerance at entry, allowing detec-
tion of changes on low-dose thiazide. Subsequently, two
small crossover studies in about 40 patients showed a rise
in 2 h glucose within 4 weeks of treatment with bendroﬂu-
methiazide 5 mg or HCTZ 50 mg, with a highly signiﬁcant
difference from the 2 h glucose during 4 weeks of treat-
ment with amiloride 20 mg (ﬁgures 1 and 2).12
PATHWAY-3 will test whether the apparent superiority
of amiloride, in protecting glucose tolerance, is
Figure 1 Evidence for dose–
response to thiazide diuretics (A).
Comparison of blood pressure
response to dose-doubling of a
calcium-channel blocker,
nifedipine and diuretic
combination, hydrochlorothiazide
and amiloride, in the INSIGHT
study. The figure shows the
response in patients achieving
target blood pressure,
140/90 mm Hg, on low-dose (left
panel) or high-dose (right panel)
monotherapy. (Unpublished data
from reference 6) (B).
Comparison of blood pressure
response to dose-doubling of
three types of
diuretic-bendroflumethiazide,
amiloride, spironolactone.
(Data redrawn from ref. 8).
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maintained over 6 months of treatment, and translates
into measurable differences in HbA1c. The study will be
large enough for secondary estimates of mechanism, for
example, the 0 and 30 min plasma insulin, to determine
whether the main drug effects are on insulin secretion
or sensitivity, and are inﬂuenced by the opposite effects
of the two diuretics on plasma K+. However, owing to the
lack of long-term study of amiloride other than in com-
bination with HCTZ, the study is also evaluating a group
in which the two diuretics are used in combination. If
we demonstrate that HCTZ 25 mg+amiloride 10 mg
achieves the same (or greater) blood pressure reduction
as HCTZ 50 mg, without an adverse effect on OGTT,
this could become the recommended diuretic treatment
for hypertension in the future.
In order to maximise recruitment, while also maximis-
ing sensitivity to detect changes in OGTT, the trial is
open to most of those patients with hypertension in
whom diuretic is a reasonable next option, providing
they have one feature of the metabolic syndrome—
additional to hypertension. This broad eligibility allows
us also to assess safety of amiloride in combination with
all commonly used antihypertensive drugs.
The initial protocol was approved by the Medicines
and Healthcare Products Regulatory Agency (MHRA)
on 8 May 2009, and is visible at https://www.
clinicaltrialsregister.eu/ctr-search/trial/2009-010068-41/
GB#A. This was not registered until 2015, because of the
prior registrations with MHRA and UKCRN and local
advice that these sufﬁced. The current protocol is V.8, as
approved on 13 February 2013. Any further amend-
ments will be approved by Research Ethics and MHRA
and registered also with clinicaltrials.gov.
Primary objectives
The primary objective of the study is to determine
whether a K+-sparing diuretic can be safely substituted
for, or combined with, a thiazide diuretic in order to
maximise the long-term beneﬁts of diuretic treatment.
Secondary objectives
The secondary objectives of the study are:
▸ To demonstrate whether half-dose combination of
two classes of diuretic improve efﬁcacy and tolerabil-
ity of diuretics, compared to taking one class alone.
▸ To evaluate the mechanism of changes in glucose tol-
erance, particularly whether these are related to
changes in K+.
▸ To determine whether a baseline measurement of
plasma renin, measured on various background treat-
ment permutations predicts whether patients’ blood
pressure is likely to be improved by addition of either
low-dose or high-dose diuretic
▸ To determine the best predictors of patients whose
glucose tolerance will be impaired by addition of thia-
zide diuretic.
A further secondary objective is to establish a reposi-
tory of pharmacogenetic samples and investigate rela-
tionships between genetic factors and pharmacodynamic
responses.
METHODS AND ANALYSIS
Trial design
Overall trial design
This is a parallel-group, randomised, double-blind, mul-
ticentre trial, comparing three treatment strategies in
patients with hypertension, an indication for diuretic
treatment, and at least one other component (ie, add-
itional to hypertension) of the metabolic syndrome.
Following a month’s placebo run-in, patients receive
their randomised treatment (diuretic) in addition to
existing background therapy for 6 months, with an
OGTT at the beginning, middle and end of this period.
The dose of each diuretic is doubled after the second
(3-month) OGTT. The trial design is outlined in the
ﬂow chart (ﬁgure 2).
Study population
Inclusion criteria are shown in box 1. These are intended
to enable recruitment of most patients in whom addition
of diuretic might be part of usual practice, enriched for
patients most likely to be at risk of develop type 2 DM
during long-term treatment with thiazide diuretic.
Figure 2 Trial schematic.
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The PATHWAY programme anticipated changes to the
deﬁnition of hypertension introduced by the National
Institute for Health and Care Excellence (NICE) guid-
ance of 2011. The trials use home BP measurements as
an outcome measure, and patients are required to
exceed threshold levels of both clinic BP (at screening
and/or randomisation) and home BP (at randomisa-
tion). Initially we set the clinic threshold at 145 mm Hg,
until we had enough experience within the trial of
adding high-dose hydrochlorothiazide or amiloride to
multiple background drugs. The threshold was then
reduced, to 140 mm Hg (see box 1).
Recruitment and randomisation of participants
Potentially suitable patients are identiﬁed from hospital
and general practice populations. Written informed
consent is obtained from participants by a medical inves-
tigator. The research nurse records baseline variables,
takes blood and urine for baseline biochemistry and
haematology and records the medical history. Blood
samples are analysed at the local health service labora-
tory according to usual practice. Serum for future ana-
lyses and blood for future genetic analyses are stored by
centres. Subjects who have given informed consent, and
meet the inclusion and exclusion criteria at the end of a
month’s placebo run-in, are randomised to receive
hydrochlorothiazide 25 mg daily, amiloride 10 mg daily,
or a combination of hydrochlorothiazide 12.5 mg and
amiloride 5 mg daily, each in addition to any other anti-
hypertensive drug being taken at the time of randomisa-
tion. Randomisation is performed by contacting a
central computerised randomisation facility based at the
Robertson Centre for Biostatistics, University of Glasgow
by telephone or via a web-based service.
Trial treatments
Initial treatment is the three groups described above.
After 3 months, each of the groups are force-titrated to
twice the starting dose, namely hydrochlorothiazide
50 mg daily, amiloride 20 mg daily, or a combination of
hydrochlorothiazide 25 mg and amiloride 10 mg daily.
These three groups are shown in the ﬂow diagram
(ﬁgure 2). Trial medication is provided in identical-
looking containers for each of the three assignments by
the Royal Free Hospital Pharmacy, and labelled without
use of the drug name, according to a randomisation
schedule provided by the Robertson Centre, University
of Glasgow. None of the investigators, patients or labora-
tory staff undertaking the primary outcome measures
are informed of the assignment. A 24 h telephone
unblinding service is provided by the Data Management
Centre for instances where principal investigators
believe that treatment of an adverse event may be com-
promised by their not knowing treatment assignment.
Compliance has been assessed by returned tablet
counts.
Tolerability
Adverse events are recorded in the electronic case
record form at each visit. A 2-week drug holiday is per-
mitted at any point where the investigator considers this
may allow subjects to remain in the trial without early
withdrawal.
Trial procedures
These are shown for each visit in the schedule of assess-
ments (table 1). There are three principal visits, at 0, 12
and 24 weeks, at which subjects have an OGTT. Blood
glucose is measured at 0, 30, 60, 120 min and insulin at
0 and 30 min. At these visits, blood is also collected for
electrolytes and estimated-glomerular ﬁltration rate
(eGFR), plasma renin, glycated haemoglobin (HbA1c)
and plasma lipids. Electrolytes and eGFR are also
checked at 2 and 14 weeks, namely 2 weeks after initi-
ation and dose-doubling of trial diuretic medication.
Seated home blood pressure readings are recorded
(morning and evening, in triplicate) over 4 days prior to
each of the three principal visits, using the Microlife
WatchBP monitor. Clinic blood pressure is measured in
triplicate at each visit, by the same monitor. For analyses
of home blood pressure, we will use the average of the
last 18 recordings prior to the visit—that is, from days
−1, −2 and −3 if all recordings have been undertaken.
For clinic blood pressure, we will analyse the average of
readings 2 and 3.
Trial end points
Primary end point
The primary study end point is the difference in blood
glucose, measured 2 h after oral ingestion of a 75 g
glucose drink, between the ﬁnal day of the placebo
run-in and at the end of 3 months and 6 months of
blinded treatment.
Box 1 Inclusion criteria
1. Age 18-80
2. Diagnosis of hypertension according to BHS criteria
3. Systolic blood pressure (SBP) on permitted background treat-
ment ≥140 mm Hg and home BP ≥130 mm Hg.
4. Indication for diuretic treatment as a treatment option for the
patient’s uncontrolled hypertension:
A. Untreated + (age >55 AND/OR Black AND/OR renin <12 mU/L)
OR
B. Receiving one or any permutation of the following:
ACEi, ARB, β-blocker, CCB, direct renin inhibitor
5. At least one other component (ie, additional to hypertension)
of the metabolic syndrome (reduced high-density lipoprotein
(HDL), raised triglycerides, glucose, waist circumference)*
*Definition of Metabolic Syndrome according to the International
Diabetes Federation, 2006:
Central obesity (waist circumference >94 cm male (>90 if Asian),
>80 female plus two of:
▸ SBP ≥130 or diastolic blood pressure ≥85 mm Hg
▸ Fasting glucose >5.6 mmol/L
▸ Fasting triglycerides >1.7 mmol/L (or on treatment)
▸ HDL <1.03 mmol/L males, <1.29 mmol/L females (or on
treatment)
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Secondary end points
These are:
▸ Difference in area under the curve of the OGTT
between the ﬁnal day of the placebo run-in, and at the
end of 3 months and 6 months of blinded treatment
▸ Difference in plasma insulin at 30 min, between the
ﬁnal day of the placebo run-in, and at the end of
3 months and 6 months of blinded treatment
▸ Difference in fasting serum lipids, between the ﬁnal
day of the placebo run-in, and at the end of 3 months
and 6 months of blinded treatment
▸ The change in home systolic BP from end of placebo
run-in to the end of 3 months and 6 months of
blinded treatment.
▸ The change in clinic systolic BP from end of placebo
run-in to the end of 3 months and 6 months of
blinded treatment.
▸ The natriuretic response, as assessed from the com-
pensatory increase in plasma renin from end of
placebo run-in to the end of 3 months and 6 months
of blinded treatment.
▸ Prediction, by baseline plasma renin, of clinic and
home SBP response to each treatment.
Data handling and record keeping
Study data is recorded by remote data entry into a web-
based electronic case report form (eCRF) developed for
the study by the Robertson Centre, Glasgow. eCRF data
is anonymous and will identify study subjects by their
assigned study numbers only. All missing data, possible
duplication and data outside pre-set limits for each par-
ameter, is queried by the Management Centre, and will
be internally validated before database lock.
Data analysis
Sample size determination
Based on at least 80% power to detect a mean difference
in glucose between any two of the treatment arms of
1 mmol/L (SD=2.2 mmol/L) using two-sample t tests with
a 1% signiﬁcance level, 414 patients are required. This is
the observed difference in 2 h glucose in the largest previ-
ous trial of glucose intolerance caused by HCTZ.11
Adjusting for an anticipated dropout proportion of 15%,
486 patients are required overall—162 in each treatment
arm.
Analysis will be performed on the full analysis popula-
tion—deﬁned as all patients with at least one postbase-
line visit—on an Intention-To-Treat basis. For sensitivity,
all analyses will also be performed on the per-protocol
population—deﬁned as all patients with at least one post
baseline visit and excluding those with any form of
major violation of the study.
Recruitment started in November 2009, and is
expected to ﬁnish during 2015.
Statistical plan
In order to meet the primary objective of determining
whether amiloride should be substituted for, or added
to, hydrochlorothiazide, the study has a hierarchical
coprimary end point. The ﬁrst-tested comparison will be
amiloride versus HCTZ. The second tested will be com-
bination versus HCTZ. A mixed effects model will be
used to compare the 2 h glucose on OGTT between the
three treatment groups (baseline, 12 and 24 weeks).
This model will adjust for baseline covariates.
For secondary analyses, the primary analysis will be
repeated but with the area under the curve (AUC) of the
OGTT as the dependent variable. Mixed effects models
will be used to estimate treatment effects for home and
clinic SBP, and for HbA1c. Analysis of covariance will be
used to compare: insulin (fasting, and rise at 30 min
during OGTT), HbA1c, lipid proﬁle, renin mass and
weight at the end of study between the three treatment
groups adjusting for baseline measures. Logistic models
will be used to compare the proportion of subjects to
Box 2 Exclusion criteria
1. Diabetes (types 1 or 2)
2. Secondary hypertension
3. Estimated-glomerular filtration rate < 45 mLs/min
4. Plasma K+ outside normal range on two successive mea-
surements during screening
5. Clinic systolic blood pressure >200 mm Hg or diastolic blood
pressure >120 mm Hg, with principal investigator (PI) discre-
tion to override if home BP measurements are lower
6. Requirement for diuretic therapy (other than for
hypertension)
7. Absolute contraindications to any of the study drugs (listed
on their data sheet)
8. Current therapy for cancer
9. Anticipation of change in medical status during course of
trial (eg, planned surgical intervention requiring >2 weeks
convalescence, actual or planned pregnancy)
10. Inability to give informed consent
11. Not on stable doses of all hypertensive medications to be
continued throughout the study for a minimum of 4 weeks
prior to randomisation, or not normally less than 2 weeks if
early randomisation is required at the discretion of the PI.
12. Participation in a clinical study involving an investigational
drug or device within 4 weeks of screening.
13. Any concomitant condition that, in the opinion of the investi-
gator, may adversely affect the safety and/or efficacy of the
study drug or severely limit the subject’s lifespan or ability to
complete the study (eg, alcohol or drug abuse, disabling or
terminal illness, mental disorders).
14. Treatment with any of the following prohibited medications:
A. Oral corticosteroids within 3 months of screening.
B. Chronic use (defined as ≥3 days of treatment per week)
of non-steroidal anti-inflammatory drugs (NSAIDs) other
than acetylsalicylic acid.
C. The use of short-acting oral nitrates within 4 h of screen-
ing or any subsequent study visit; long-acting oral nitrates
(eg, Isordil) is permitted, but the dose must be stable for
at least 2 weeks prior to screening and randomisation.
15. A pill count will be made at the end of the 4-week run-in
period and those with adherence <70% will be excluded
from randomisation
Brown MJ, et al. BMJ Open 2015;5:e008086. doi:10.1136/bmjopen-2015-008086 5
Open Access
Table 1 Schedule of measurements
Assessment Screening
Placebo run-in
D-3, D-2, D-1 Week 0 Week 2
Week 11
D-3, D-2, D-1 Week 12 Week 14
Week 23
D-3, D-2, D-1 Week 24
Informed consent x
Demography x
Medical history x x
Medical examination x
Concomitant medications x x x x x x
Inclusion/exclusion checks x x
Height and weight* x x x x
Clinic BP† x x x x
Home BP‡ x x x
ECG x
Waist and hip circumference x x
Urinalysis x x x
Blood Tests:
Electrolytes (including bicarbonate) x x x x x x
Glucose (non-fasting) x
Full-blood count x x x
Lipid profile x x x x
Uric acid x x x
Ca++ x x x
Renin x x x
Pharmacogenetics§ x
HbA1c x x x
Glucose(fast)¶ x x x
Insulin¶ x x x
OGTT** x x x
Pregnancy serum†† x
Adverse events x x
Randomisation x
Study medication dispensed x x x
Compliance check x x x
Dose force titrated x
*Height recorded at first visit only.
†Clinic BP will be measured following 10 min rest and recorded in triplicate.
‡Home BP will be measured using the BP device given by clinic at approximately 08.00 and 20:00 on the 4 days before the clinic visit. Patients will be asked to take triplicate reading after
10 min rest and to record the second and third on the proforma provided.
§Pharmacogenetics sample to be taken where specific informed consent has been given. Sampling will typically be at baseline (day 0), but may be at any time later in the study.
¶ That is, baseline sample for OGTT.
**Glucose at 0, 30, 60, 120 min; insulin at 0, 30 min.
††Serum HcG may be replaced by early morning urine specimen for human choriogonadotropin testing.
BP, blood pressure; HbA1c, glycated haemoglobin; OGTT, oral glucose tolerance test.
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achieve target SBP (deﬁned as ≤140 mm Hg) at 24 weeks
between the treatment groups. Logistic models will be
used to compare the proportion of patients who develop
diabetes (deﬁned by fasting glucose ≥7 mmol/L or 2 h
glucose ≥11.1 mmol/L or HbA1c ≥6.5%) by the end of
the study between the three treatment groups. The cov-
ariates in analyses of BP will include baseline plasma
renin as a potential predictor of response.
Patients who withdraw from the study before ﬁnal visit
will be included in the primary analysis if they have at
least one postrandomisation glucose tolerance test, and
missing data imputed by application of last observation
carried forwards. Patients with data missing from any
timepoint required for analysis, and patients in whom
major violation of the protocol is documented by investi-
gators, or detected by the data management centre, will
be excluded from per-protocol analysis.
There will be no interim analysis, no stopping rules
and no data monitoring committee. This is because all
treatments are being used for licensed indications, and
have been so used for several decades. We do not there-
fore anticipate any unexpected hazard that has eluded
detection during many hundreds of thousands of
person-years exposure; and the study is not powered to
detect any signiﬁcant differences in serious morbidity or
mortality between treatment groups.
Ethics and dissemination
PATHWAY-3 is approved by Cambridge South Ethics
Committee and the MHRA. The results will be pub-
lished in a peer-reviewed journal, and presented to
national and international meetings. All authors of this
article will have full access to the complete data set,
subject only to agreement by coauthors to uses of the
data. Authorship of future articles reporting outcomes
will represent multidisciplinary input at each site, with
the articles being written by a subset of the current
authorship. There are no current plans to make anon-
ymised participant-level data publicly available. However
lay-friendly summaries of our ﬁndings will be sent to all
our patients, and we expect to work with the British
Heart Foundation to maximise patient and public access
to the ﬁndings.
Ancillary and post-trial care
During the trial all patients are covered by the National
Health Service (NHS) indemnity. We expect most
patients to continue diuretic treatment in addition to
other pretrial background therapy that has been contin-
ued during the trial.
Study sponsorship: monitoring, audit, quality control and
quality assurance
The trial is sponsored by the University of Cambridge
and Cambridge University Hospitals NHS Foundation
Trust, contact stephen.kelleher@addenbrookes.nhs.uk.
Trial investigators will permit authorised third parties
access to the trial site and medical records relating to
trial subjects. This will include, but not necessarily be
restricted to, access for trial-related monitoring, audits,
Ethics Committee review and regulatory inspections. We
do not expect funders or sponsors to be involved in data
analysis or reporting.
Associated projects
This study (PATHWAY-3) is one of three complementary
studies in a British Heart Foundation-funded pro-
gramme which will investigate optimal treatment for
patients with hypertension. PATHWAY-1 will investigate
whether initial treatment with a combination of drugs is
more effective in achieving a sustained target pressure
than starting with monotherapy and adding a second
drug. PATHWAY-2 will recruit patients with more severe
hypertension than either PATHWAY-1 or PATHWAY-3,
and compare the blood pressure response to each of the
three classes recommended by current guidelines.
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